![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
0
EU WC
Listed Suppliers
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
https://www.globenewswire.com/news-release/2024/05/06/2875645/29517/en/MannKind-Receives-U-S-FDA-Fast-Track-Designation-for-Clofazimine-Inhalation-Suspension-for-the-Treatment-of-Nontuberculous-Mycobacterial-NTM-Lung-Disease.html
https://www.globenewswire.com/news-release/2024/04/29/2871043/29517/en/MannKind-Announces-IND-Clearance-From-U-S-FDA-to-Start-Phase-3-Study-of-Clofazimine-Inhalation-Suspension-for-Nontuberculous-Mycobacterial-NTM-Lung-Disease.html
https://www.midas-pharma.com/en/latest-activities/midas-pharma-obtains-cep-for-clofazimine/
https://www.fiercebiotech.com/research/could-low-cost-leprosy-drug-clofazimine-be-repurposed-for-covid-19
https://www.biospace.com/article/releases/mannkind-expands-its-pipeline-with-the-acquisition-of-qrumpharma-inc-lead-investigational-product-inhaled-clofazimine-designated-by-the-fda-as-an-orphan-drug-and-qualified-infectious-disease-product/?s=79